List of Excipients in Branded Drug SINCALIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi USA LLC	SINCALIDE	sincalide	63323-579	ARGININE HYDROCHLORIDE	1969-12-31
Fresenius Kabi USA LLC	SINCALIDE	sincalide	63323-579	LYSINE HYDROCHLORIDE	1969-12-31
Fresenius Kabi USA LLC	SINCALIDE	sincalide	63323-579	MANNITOL	1969-12-31

Sincalide Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Sincalide is a short synthetic cholecystokinin peptide marketed primarily as an injectable diagnostic adjunct for gallbladder and pancreatic imaging. The reference product, Kinevac, uses a simple lyophilized formulation with mannitol as the principal documented inactive ingredient. The strongest commercial opportunities are improved reconstitution, ready-to-use presentations, supply continuity, lower-dose waste reduction, and global injectable competition rather than broad new therapeutic indications.

What is sincalide and how is it marketed?

Sincalide is an eight-amino-acid synthetic peptide analog of cholecystokinin. It stimulates gallbladder contraction and pancreatic secretion. Its principal use is diagnostic imaging, including hepatobiliary procedures and assessment of gallbladder function.

Attribute	Sincalide
Active ingredient	Sincalide
Drug class	Synthetic gastrointestinal peptide
Primary use	Diagnostic stimulation during biliary and pancreatic imaging
Dosage form	Sterile lyophilized powder for injection
Reference product	Kinevac
Typical vial strength	5 mcg
Administration	Intravenous infusion after reconstitution and dilution
Documented excipient	Mannitol
Primary manufacturer associated with Kinevac	Bracco Diagnostics
FDA pathway	Approved prescription drug product
Biosimilar pathway	Not applicable
Main commercial buyers	Hospitals, radiology departments, nuclear medicine centers, imaging facilities

The product’s commercial value is linked to procedure volume, not chronic prescription use. That creates a concentrated but defensible market in which reliability, vial utilization, pharmacy workflow and imaging-center availability influence purchasing decisions.

What excipients are used in the Kinevac formulation?

The Kinevac label identifies mannitol as the principal inactive ingredient. Each vial contains 5 mcg of sincalide and approximately 23 mg of mannitol, with reconstitution using sterile sodium chloride solution according to the product instructions.[1]

Mannitol likely performs several formulation functions:

• Provides bulking material for the lyophilized cake.
• Improves the physical structure of the freeze-dried product.
• Supports dose uniformity at the very low 5-mcg peptide load.
• Contributes to an acceptable reconstitution profile.
• Avoids the reducing-sugar chemistry associated with some carbohydrate excipients.

The reference formulation is commercially conservative. It does not require a large excipient system because the product is administered in very small quantities and is not intended for long-term storage after reconstitution.

What are the formulation constraints for sincalide?

Sincalide is a low-dose peptide with several development constraints:

1. Peptide adsorption to glass, elastomeric closures and infusion-contact surfaces.
2. Aggregation or precipitation during reconstitution or dilution.
3. Degradation caused by oxidation, deamidation, hydrolysis or peptide bond cleavage.
4. Sensitivity to pH, ionic strength and temperature.
5. Low drug concentration, which increases the relative impact of surface losses.
6. Short procedural timelines that favor rapid and predictable reconstitution.

The most important excipient objective is not simply maximizing chemical stability. It is preserving the delivered dose through vial reconstitution, syringe preparation, dilution and infusion.

Which excipients could improve a next-generation sincalide product?

A development program should screen excipients by function rather than by selecting a large formulation system. The primary candidates are mannitol, trehalose, sucrose, polysorbate 20, polysorbate 80, poloxamer 188, methionine, histidine and phosphate or citrate buffers.

Excipient class	Candidate	Potential function	Principal development concern
Bulking agent	Mannitol	Cake structure and dose distribution	Crystallization and phase behavior
Stabilizing sugar	Trehalose	Lyoprotection and amorphous stabilization	Hygroscopicity and cake collapse
Stabilizing sugar	Sucrose	Peptide stabilization during freezing and drying	Residual moisture and glass transition
Surfactant	Polysorbate 20	Reduces surface adsorption	Peroxide-related oxidation and degradation
Surfactant	Polysorbate 80	Reduces interfaces and adsorption	Oxidation, particulates and lot variability
Surfactant	Poloxamer 188	Interfacial protection	Possible formulation complexity
Antioxidant	Methionine	Oxidation control	Possible impact on pH and assay profile
Buffer	Histidine	Mild pH control	Buffer capacity at low concentration
Buffer	Phosphate	Strong pH control	Freeze-concentration effects and precipitation
Tonicity agent	Sodium chloride	Osmolality adjustment	Limited value in a highly diluted product

Is mannitol alone sufficient?

Mannitol may be sufficient for a stable lyophilized product, particularly if the process controls peptide concentration, residual moisture and cake morphology. A mannitol-only system has commercial advantages because it is simple, familiar to regulators and easy to manufacture.

A mannitol-only strategy may be less attractive if development testing shows:

• Peptide loss to container surfaces;
• Slow or incomplete reconstitution;
• Visible or subvisible particles;
• Instability after dilution into infusion fluids;
• Batch-to-batch variation in cake structure;
• Excessive sensitivity to shipping temperature excursions.

A mixed mannitol-trehalose or mannitol-sucrose system could improve amorphous stabilization, but it would require careful control of crystallinity and residual moisture. A surfactant should be added only if adsorption or agitation studies demonstrate a measurable benefit.

What formulation strategy offers the strongest commercial opportunity?

The most commercially credible strategy is a differentiated presentation rather than a radically new excipient composition.

1. Optimized lyophilized vial

An improved lyophilized vial could retain mannitol while adding a low concentration of a stabilizing sugar or surfactant. The product would target:

• Faster reconstitution;
• Lower foam formation;
• Reduced peptide adsorption;
• Longer in-use stability;
• Better tolerance to routine transport conditions.

This strategy has the lowest regulatory and manufacturing risk because it preserves the existing dosage form.

2. Ready-to-use liquid formulation

A ready-to-use liquid could eliminate reconstitution and reduce pharmacy labor. Its principal challenges are peptide stability, container adsorption, oxidation, microbial control and refrigerated distribution.

A liquid product may need:

• A low-binding container;
• A validated stopper and syringe system;
• A carefully controlled pH;
• A surfactant or protein-compatible surface treatment;
• A refrigerated shelf-life supported by real-time stability;
• A preservative-free single-dose presentation.

A prefilled syringe or small-volume vial could be valuable for imaging centers, but the commercial case depends on whether the product can achieve a meaningful shelf life without imposing costly cold-chain requirements.

3. Dual-component presentation

A kit containing sincalide and a dedicated diluent could reduce preparation variability. This approach could support standardized imaging protocols and simplify procurement. The kit would need clear compatibility data for the diluent, tubing and administration method.

4. Lower-waste dose presentation

Because the active dose is measured in micrograms, a 5-mcg vial may result in material waste when a procedure requires only a fraction of the reconstituted product. Smaller-dose vials or multi-dose formats could reduce waste, but multi-dose presentations create sterility and preservative issues.

A 1-mcg or 2-mcg presentation could be commercially attractive if dosing protocols support it. The main barrier is packaging and manufacturing cost relative to a small diagnostic market.

What patent opportunities exist for sincalide formulations?

The original sincalide composition and use rights are old. The strongest remaining patent opportunities would likely concern specific formulations, container systems, administration methods or manufacturing processes.

Potential claim areas include:

• A defined sincalide-mannitol-trehalose formulation;
• A peptide formulation with a specified pH range and residual moisture;
• A formulation that limits adsorption to glass or elastomeric components;
• A ready-to-use liquid with a defined refrigerated shelf life;
• A prefilled syringe or cartridge;
• A reconstitution system that reduces preparation time;
• A formulation with demonstrated stability after dilution;
• A lyophilization cycle linked to a specific cake structure and peptide purity profile;
• A method for preserving sincalide potency during infusion.

Patentability would depend on unexpected results. A claim covering routine substitution of sucrose for mannitol, or routine addition of polysorbate, would face substantial obviousness risk under U.S. patent law. Stronger claims would require comparative data showing an unexpected improvement in stability, dose recovery, reconstitution or in-use compatibility.

Are there active Orange Book patents for Kinevac?

The commercial record for Kinevac is primarily defined by the approved product, manufacturing controls and supply position rather than by a clearly identifiable active patent estate protecting the original sincalide molecule. The Orange Book should be checked for the current listing status, NDA data and any patent or exclusivity information before a filing or freedom-to-operate decision.[2]

A new entrant should not assume that the absence of prominent composition-of-matter protection eliminates regulatory risk. FDA review may focus on:

• Peptide identity and impurity profile;
• Sterility assurance;
• Container-closure compatibility;
• Stability after reconstitution;
• Labeling and dosing instructions;
• Comparability of the finished dosage form.

When does sincalide lose exclusivity, and what is the generic entry risk?

Sincalide’s original molecule and early clinical uses are long past ordinary patent exclusivity. The practical entry question is therefore not loss of originator exclusivity. It is whether a competitor can develop and supply a reliable injectable product that satisfies FDA quality requirements and earns sufficient margin.

A generic or follow-on entrant could pursue an abbreviated application if the reference product and regulatory pathway support pharmaceutical equivalence. Because sincalide is a synthetic peptide, the product is not a biosimilar under the Public Health Service Act. The regulatory route would more likely involve an ANDA or, where equivalence and formulation differences require additional clinical or technical work, a 505(b)(2) application.[3]

What Paragraph IV challenges are possible?

A Paragraph IV certification could arise if the Orange Book lists an applicable patent for the reference product. The likely targets would be later-issued formulation, container or manufacturing patents, not the original sincalide molecule.

A challenger would need to evaluate:

• Whether any listed patent claims the proposed dosage form;
• Whether the proposed formulation avoids the claim limitations;
• Whether the product uses a different excipient system;
• Whether the patent covers a method of use included in the proposed label;
• Whether the patent is enforceable and commercially relevant at the planned launch date.

No reliable commercial conclusion should be based solely on the molecule’s age. A later formulation patent could still delay approval or create litigation exposure.

What method-of-use patents could protect sincalide?

Method-of-use protection for sincalide is narrower than for therapeutic drugs because the product is primarily used as a diagnostic aid. Potential claims could address:

• A specific imaging protocol;
• Timing of sincalide administration relative to radiotracer injection;
• Dose selection for a defined patient population;
• Use in patients with particular gallbladder or pancreatic conditions;
• Combination with a specific diagnostic imaging agent;
• A method that improves reproducibility of gallbladder ejection fraction measurements.

The commercial value of such patents would depend on whether the method is included in the FDA-approved label and whether imaging centers routinely follow the claimed protocol. A narrow method claim may have limited blocking power if physicians can use a different protocol without changing the product’s core indication.

What manufacturing and IP barriers affect sincalide competition?

The main barriers are technical and operational.

Peptide manufacturing

Sincalide requires controlled synthetic peptide manufacturing, purification and characterization. Critical attributes include:

• Correct amino-acid sequence;
• Correct sulfation state where applicable;
• Control of deletion sequences and side products;
• Peptide purity;
• Potency in a validated bioassay;
• Low endotoxin;
• Sterility;
• Stability through lyophilization.

The active pharmaceutical ingredient may be manufactured by solid-phase peptide synthesis, followed by cleavage, purification and final characterization. The process must control impurities that can be difficult to separate when the target peptide is present at a small scale.

Injectable manufacturing

The finished product requires:

• Sterile filtration or aseptic processing;
• Validated lyophilization;
• Container-closure integrity testing;
• Extractables and leachables assessment;
• Particulate control;
• In-use stability testing;
• Compatibility with dilution fluids and administration sets.

For a low-volume diagnostic product, the cost of validation and sterile manufacturing can be more material than the cost of the peptide itself.

Supply-chain barriers

Commercial success depends on consistent availability to imaging centers. A competitor with a lower price but unreliable supply may fail to displace the reference product. Dual-source peptide API qualification, redundant fill-finish capacity and controlled cold-chain logistics can create practical differentiation.

Which commercial opportunities are most attractive?

Opportunity	Commercial appeal	Development complexity	Likely strategic value
Improved lyophilized vial	High	Low to moderate	Best initial target
Ready-to-use liquid vial	High	High	Strong workflow differentiation
Prefilled syringe	Moderate to high	High	Reduces preparation steps
Smaller-dose vial	Moderate	Moderate	Reduces waste in selected protocols
Dedicated diluent kit	Moderate	Moderate	Supports standardized workflow
Global generic injectable	Moderate	Moderate	Depends on local competition
New therapeutic indication	Low to moderate	Very high	Weak near-term fit
Novel formulation patent	Moderate	High	Valuable if supported by unexpected results

The most attractive program is an optimized lyophilized product with a differentiated container-closure system and documented post-reconstitution stability. It can preserve the manufacturing familiarity of the reference product while creating a basis for product claims, regulatory differentiation and hospital purchasing value.

How does sincalide compare with competing diagnostic agents?

Sincalide has no direct one-for-one substitute across all diagnostic protocols. Its alternatives depend on the clinical objective and institutional practice.

Product or approach	Primary role	Competitive relationship
Sincalide	Pharmacologic gallbladder stimulation	Reference diagnostic peptide
Fatty meal stimulation	Physiologic gallbladder stimulation	Non-drug substitute in some protocols
Cholecystokinin analogs	Gallbladder and pancreatic stimulation	Potential formulation or regional alternatives
Other imaging protocols	Diagnostic assessment without sincalide	Indirect competitive pressure
Compounded or imported peptide products	Supply substitution	Quality and regulatory risk

Sincalide’s strongest competitive advantage is standardized pharmacologic stimulation. Its weakness is limited market size, procedural dependence and the need for sterile injectable handling.

What FDA and regulatory issues matter most?

A new sincalide product should be designed around the intended regulatory pathway from the beginning. Key regulatory questions include:

• Whether the product qualifies as pharmaceutically equivalent to Kinevac;
• Whether the proposed excipients are present in the reference product;
• Whether a new excipient requires additional safety support;
• Whether the product is a generic injectable or a 505(b)(2) product;
• Whether the label includes the same diagnostic uses and dosing instructions;
• Whether reconstituted and diluted stability supports the proposed instructions;
• Whether the product has adequate comparative peptide characterization;
• Whether the container system changes delivered dose or peptide recovery.

The FDA label, Drugs@FDA record and Orange Book should be used together. The label identifies composition and administration. Drugs@FDA provides approval documents and regulatory history. The Orange Book identifies listed patents and exclusivity relevant to abbreviated applications.[1-3]

Key Takeaways

• Sincalide is a synthetic diagnostic peptide marketed primarily as a lyophilized injectable.
• Kinevac uses mannitol as the documented principal excipient.
• The leading formulation opportunity is an improved lyophilized vial with better reconstitution, dose recovery and in-use stability.
• Ready-to-use liquid and prefilled syringe formats offer greater workflow value but create higher stability and container-closure burdens.
• The original sincalide molecule is not the main exclusivity barrier.
• Potential later patents would likely concern formulations, delivery systems, manufacturing processes or specific imaging methods.
• Sincalide is not subject to the biosimilar pathway.
• Generic entry risk is driven more by sterile manufacturing, peptide quality, supply reliability and FDA equivalence requirements than by molecule-level patent protection.
• A mannitol-trehalose or mannitol-surfactant formulation should be pursued only if comparative studies show improved peptide recovery or stability.
• The best commercial positioning is a reliable, low-waste, easy-to-administer diagnostic injectable for hospitals and imaging centers.

FAQs

Can sucrose replace mannitol in a sincalide formulation?

Yes, sucrose can provide lyoprotective effects, but it may alter cake structure, residual moisture and reconstitution behavior. A sucrose replacement would require comparative stability and process data.

Is a liquid sincalide injection commercially feasible?

Yes, but it is technically more demanding than a lyophilized vial. The main risks are oxidation, adsorption, aggregation, container interaction and refrigerated shelf-life requirements.

Would a sincalide prefilled syringe have patent value?

It could, if the syringe system demonstrates improved peptide recovery, reduced preparation error, or meaningful stability advantages. A generic claim to placing sincalide in a syringe would face stronger patentability challenges.

Is sincalide eligible for biosimilar approval?

No. Sincalide is a synthetic peptide drug rather than a biological product approved under the biosimilar framework. An entrant would generally evaluate an ANDA or 505(b)(2) strategy.

What is the strongest commercial differentiator for a sincalide competitor?

Supply reliability combined with simpler preparation is likely to be more valuable than a modest price reduction. A stable, rapidly reconstituted vial or ready-to-use presentation could create the clearest purchasing advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Kinevac (sincalide) injection prescribing information. Bracco Diagnostics.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2015). Q8(R2) pharmaceutical development. International Council for Harmonisation.

5. U.S. Food and Drug Administration. (2023). Q9(R1) quality risk management. International Council for Harmonisation.

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.